NCT05676034View on ClinicalTrials.gov

AMX0035 in Adult Patients With Wolfram Syndrome

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 3, 2023

Primary Completion Date

July 23, 2024

Study Completion Date

December 31, 2026

Conditions
Wolfram Syndrome
Interventions
DRUG

AMX0035

AMX0035

Trial Locations (1)

63110

Washington University, St Louis

Sponsors
All Listed Sponsors
lead

Amylyx Pharmaceuticals Inc.

INDUSTRY